Abstract 6253: SP-3164, a novel molecular glue degrader with activity in preclinical models of multiple myeloma
Aundrietta D. Duncan(Io Therapeutics (United States)), P. Leif Bergsagel(Mayo Clinic in Arizona), V. Jacques(Centre National de la Recherche Scientifique), Sheila H. DeWitt, Nadeem Q. Mirza, Steve Horrigan, Daniela Y. Santiesteban
Cited by 1
Related Papers
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
|Mayo Clinic Proceedings|2009|625
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Stimulated Emission Depletion Microscopy Resolves Individual Nitrogen Vacancy Centers in Diamond Nanocrystals
|ACS Nano|2013|135
TRIM24 Is a p53-Induced E3-Ubiquitin Ligase That Undergoes ATM-Mediated Phosphorylation and Autodegradation during DNA Damage
|Molecular and Cellular Biology|2014|106